Lysosomotropic agents as HCV entry inhibitors

Virology Journal

Volumn 8, Issue , 2011, Pages

  Ashfaq, Usman A ^a   Javed, Tariq ^a   Rehman, Sidra ^a   Nawaz, Zafar ^b   Riazuddin, Sheikh ^c  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM CHLORIDE; ANTIVIRUS AGENT; CHLOROQUINE; LYSOSOMOTROPIC AGENT; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL MEMBRANE; CELL PH; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENDOCYTOSIS; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL; LYSOSOME; NONHUMAN; PH; TOXICOLOGY; VIRUS ENTRY; VIRUS INFECTIVITY; CELL LINE; DRUG EFFECT; GENETICS; HEPATITIS C; METABOLISM; PHYSIOLOGY; VIROLOGY;

HEPATITIS C VIRUS;

AMMONIUM CHLORIDE; ANTIVIRAL AGENTS; CELL LINE; CHLOROQUINE; HEPACIVIRUS; HEPATITIS C; HUMANS; LYSOSOMES; VIRUS INTERNALIZATION;

EID: 79953858689     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-163     Document Type: Article

References (27)

1. Hepatitis C virus infection. BJ Thomson RG Finch, Clin Microbiol Infect 2005 11 86 94 10.1111/j.1469-0691.2004.01061.x 15679481 (Pubitemid 40253812)
2. The role of the hepatitis C virus glycoproteins in infection. M Flint JA McKeating, Rev Med Virol 2000 10 101 117 10.1002/(SICI)1099-1654(200003/04)10: 2<101::AID-RMV268>3.0.CO;2-W 10713597 (Pubitemid 30175425)
3. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. M Hsu J Zhang M Flint C Logvinoff C Cheng-Mayer CM Rice JA McKeating, Proc Natl Acad Sci USA 2003 100 7271 7276 10.1073/pnas.0832180100 12761383 (Pubitemid 36706428)
4. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. F McOmish PL Yap BC Dow, J Clin Microbiol 1994 32 884 892 7913097 (Pubitemid 24100056)
5. Hepatitis C virus type 1b (II) infection in France and Italy. JB Nousbaum S Pol B Nalpas Group atCS, Ann Intern Med 1995 122 161 168 7810932
6. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. M Idrees S Riazuddin, BMC Infect Dis 2008 8 69 10.1186/1471-2334-8-69 18498666
7. Chronic hepatitis C virus infection. SL Flamm, Jama 2003 289 2413 2417 10.1001/jama.289.18.2413 12746366 (Pubitemid 37430175)
8. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. M Cornberg H Wedemeyer MP Manns, Curr Gastroenterol Rep 2002 4 23 30 10.1007/s11894-002-0034-y 11825538
9. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. S Khakoo P Glue L Grellier B Wells A Bell C Dash I Murray-Lyon D Lypnyj B Flannery K Walters GM Dusheiko, Br J Clin Pharmacol 1998 46 563 570 10.1046/j.1365-2125.1998.00836.x 9862245 (Pubitemid 28522120)
10. Side effects of therapy for chronic hepatitis C. MW Russo MW Fried, Gastroenterology 2003 124 1711 1719 10.1016/S0016-5085(03)00394-9 12761728 (Pubitemid 36617688)
11. Weakly basic amines inhibit the proteolytic conversion of proalbumin to serum albumin in cultured rat hepatocytes. K Oda Y Ikehara, Eur J Biochem 1985 152 605 609 10.1111/j.1432-1033.1985.tb09238.x 3902474 (Pubitemid 16192365)
12. Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in cultured rat hepatocytes. K Oda Y Koriyama E Yamada Y Ikehara, Biochem J 1986 240 739 745 3493770 (Pubitemid 17009991)
13. Commentary. Lysosomotropic agents. C de Duve T de Barsy B Poole A Trouet P Tulkens F Van Hoof, Biochem Pharmacol 1974 23 2495 2531 10.1016/0006-2952(74) 90174-9 4606365
14. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. B Poole S Ohkuma, J Cell Biol 1981 90 665 669 10.1083/jcb.90.3.665 6169733 (Pubitemid 12254922)
15. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. MJ Vincent E Bergeron S Benjannet BR Erickson PE Rollin TG Ksiazek NG Seidah ST Nichol, Virol J 2005 2 69 10.1186/1743-422X-2-69 16115318
16. Effects of chloroquine on viral infections: an old drug against today's diseases? A Savarino JR Boelaert A Cassone G Majori R Cauda, Lancet Infect Dis 2003 3 722 727 10.1016/S1473-3099(03)00806-5 14592603 (Pubitemid 37345352)
17. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. A Savarino L Gennero HC Chen D Serrano F Malavasi JR Boelaert K Sperber, Aids 2001 15 2221 2229 10.1097/00002030-200111230-00002 11698694 (Pubitemid 34059828)
18. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. L Di Trani A Savarino L Campitelli S Norelli S Puzelli D D'Ostilio E Vignolo I Donatelli A Cassone, Virol J 2007 4 39 10.1186/1743-422X-4-39 17477867
19. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. K Sperber G Chiang H Chen W Ross E Chusid M Gonchar R Chow O Liriano, Clin Ther 1997 19 913 923 10.1016/S0149-2918(97)80045-8 9385480 (Pubitemid 27508927)
20. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. NI Paton J Aboulhab, HIV Med 2005 6 13 20 10.1111/j.1468-1293.2005.00259.x 15670247 (Pubitemid 40268111)
21. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. T Mosmann, J Immunol Methods 1983 65 55 63 10.1016/0022-1759(83)90303-4 6606682 (Pubitemid 14203433)
22. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. B Bartosch J Dubuisson FL Cosset, J Exp Med 2003 197 633 642 10.1084/jem.20021756 12615904 (Pubitemid 36314658)
23. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. HE Drummer A Maerz P Poumbourios, FEBS Lett 2003 546 385 390 10.1016/S0014-5793(03)00635-5 12832074 (Pubitemid 36782444)
24. Chloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion. B Thorens P Vassalli, Nature 1986 321 618 620 10.1038/321618a0 3086747 (Pubitemid 16042215)
25. Inhibition of vesicular stomatitis virus glycoprotein expression by chloroquine. BJ Dille TC Johnson, J Gen Virol 1982 62 Pt 1 91 103 10.1099/0022-1317-62-1-91 6290597 (Pubitemid 13239791)
26. Inhibition of human immunodeficiency virus infectivity by chloroquine. WP Tsai PL Nara HF Kung S Oroszlan, AIDS Res Hum Retroviruses 1990 6 481 489 10.1089/aid.1990.6.481 1692728
27. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. A Savarino MB Lucia E Rastrelli S Rutella C Golotta E Morra E Tamburrini CF Perno JR Boelaert K Sperber R Cauda, J Acquir Immune Defic Syndr 2004 35 223 232 10.1097/00126334-200403010-00002 15076236 (Pubitemid 38280647)